Navigation Links
NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis

United States. As in the 111 study,

patients will be 40 years, or older, with osteoarthritis in at least

one hip or knee and a diagnosis of controlled essential hypertension.

Following a one week screening period, patients will be randomized to

either one of five groups, which will receive 13 weeks of treatment

with: naproxcinod 375 mg bid (twice-daily), naproxcinod 750 mg bid,

naproxen 250 mg bid, naproxen 500 mg bid or ibuprofen 600 mg tid. At

the end of the treatment period, all patients will receive placebo for

2 weeks. 24-hour blood pressure monitoring will be conducted at

baseline and at the end of the 13-week treatment period. The primary

objective of the study is to assess the mean change from baseline in

the average 24-hour systolic blood pressure, as well as evaluating the

general safety and tolerability of naproxcinod.

Staffan Stromberg, Vice President of Drug Development at NicOx, said: "We have chosen naproxen as the comparator in the pivotal phase 3 studies, due to its well established anti-inflammatory efficacy and its perception as the least risky of the existing NSAIDs in terms of blood pressure and cardiovascular safety. In the 112 study, we will also obtain long term 24-hour blood pressure comparisons between our first CINOD and ibuprofen, the most widely used NSAID."

NOTE 1: The biological mechanisms by which NSAIDs increase blood pressure are not well understood, although an increase in blood vessel constriction, interference with antihypertensive treatment and retaining dietary salt all seem to contribute. The extent of the increase is not fully defined, although there appears to be a variation between different products, with ibuprofen and the selective COX-2 inhibitors bringing about greater increases than non- selective drugs, such as naproxen. However, all existing products have been associated with some bloo

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
2. NicOx Opens U.S. Headquarters in New Jersey
3. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 22 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 29,2008, after the market ... call at 5:00 p.m. ET, which will be open ... call, the company will review,the financial results and discuss ...
... MONTREAL, Oct. 22 Global Vision, the leader ... that 15 of the top 20 pharmaceutical companies ... risk of textual and artwork errors from,occurring in ... has resulted in a reduction of quality issues ...
... Md., Oct. 22 Micromet, Inc.,(Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune,diseases, today ... and audio,webcast on Thursday, November 6, 2008, at ... to discuss its third quarter 2008 financial results.,Micromet ...
Cached Biology Technology:Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 3Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 3Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 4
(Date:4/15/2014)... The global experts who study the deadliest infectious ... Thomas G. Ksiazek, professors at the University of Texas ... 6th annual International Symposium on Filoviruses. The filoviruses include ... to 90 percent of people infected. The current outbreak ... more than 100 deaths so far. , "This ...
(Date:4/15/2014)... University dental researchers have found a less invasive ... the mouth to study how the mouth,s natural ... isolating some specialized immune cells (white blood cells ... diseases in the mouthor reject foreign tissues, such ... more about treating and preventing such health issues ...
(Date:4/15/2014)... BETHESDA, Md. (April 15, 2014) The American ... 2014 award winners. All awards will be presented ... San Diego Marriott Hotel on Tuesday, April 29th at ... Biology (EB). , The 2014 award winners ... Jeffrey Laitman, PhD, of the Icahn School of ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3New method isolates immune cells for researchers to study how they ward off oral diseases 2American Association of Anatomists 2014 award winners 2
... Santa Barbara have discovered a caste of genetically identical ... that invades the California horn snail. The findings are ... Proceedings of the Royal Society B . "We ... defending the colony," said Armand M. Kuris, professor of ...
... Researchers at Oregon State University have reported the successful ... of nanostructure that has gained significant interest in recent ... microreactors. The findings, announced in the journal ... new nanotech applications in production of pharmaceuticals, biological sensors, ...
... Mich. A University of Michigan-led research team ... a devastating inherited kidney disorder, thanks to a new, faster ... The success offers hope that scientists can speed the ... and test drugs to treat them. The U-M ...
Cached Biology News:'Warrior worms' discovered in snails; UCSB scientists see possible biomedical applications 2'Nanosprings' offer improved performance in biomedicine, electronics 2Fast-track gene-ID method speeds rare disease search 2Fast-track gene-ID method speeds rare disease search 3
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: